Jump to a section
- What is Tesamorelin?
- Why researchers study it
- Benefits discussed in literature
- Uses discussed in research
- Mechanisms discussed in published studies
- Reported study designs and protocol examples
- Protocol table from cited sources
- Limitations and research gaps
- Documentation checklist
- Related research supplies
- More Tesamorelin research
- Sources and references
Disclosure: Peptide Bio Index is affiliated with SourcePoint Research and may earn from qualifying purchases or affiliate links.
This article summarizes published research and reported study designs. It is not medical advice, dosing guidance, or a personal-use recommendation.
Source-limited research note: The reviewed sources were incomplete, ambiguous, or insufficient for a normal article. This page labels missing details rather than guessing.
This summary synthesizes reviewed literature on tesamorelin — a growth hormone‑releasing factor analogue — focusing on what published studies and reviews report about its definition, research rationale, reported benefits, researched uses, proposed mechanisms, and documented study protocols.
What is Tesamorelin?
Tesamorelin is described in the literature as a growth hormone‑releasing factor (GHRF) analogue that has been approved for reducing excess abdominal fat in HIV‑infected patients with lipodystrophy. [S3] [S5]
Why researchers study it
Researchers study tesamorelin because it acts on the growth hormone axis and is grouped with other growth hormone secretagogues that can activate IGF‑1 signaling and influence processes relevant to tissue repair and body composition; interest also stems from broader clinical and marketplace attention to peptide therapeutics and questions about safety and effectiveness outside approved indications. [S1] [S2] [S4]
Benefits discussed in literature
Clinical trial data among people with HIV report reductions in visceral adipose tissue and in hepatic fat fraction and improvements in trunk‑to‑appendicular fat ratio compared with placebo in treated participants. [S5]
Regulatory and review literature characterizes tesamorelin as an approved therapy for reduction of excess abdominal fat in HIV‑associated lipodystrophy. [S3] [S5]
Reviews note mechanistic links between growth hormone secretagogues (a class that includes tesamorelin) and IGF‑1 signaling and satellite cell repair, which are discussed as potential biological bases for effects on body composition and tissue repair, but reviews also emphasize limited direct clinical evidence outside the approved HIV indication. [S1] [S4] [S2]
Uses discussed in research
Tesamorelin is discussed in clinical research and regulatory literature primarily for the treatment of abdominal fat accumulation in people with HIV (lipodystrophy), and has been evaluated in randomized trials within this population. [S3] [S5]
Reviews that survey peptides for orthopaedic and sports medicine applications include tesamorelin among growth hormone secretagogues evaluated for regenerative potential, but they state there is no supporting orthopaedic clinical evidence for tesamorelin at present. [S2] [S4]
Mechanisms discussed in published studies
Tesamorelin is described as a growth hormone‑releasing factor analogue; growth hormone secretagogues are reported to activate IGF‑1 signaling and have been linked in reviews to satellite cell repair and other pathways implicated in tissue regeneration. [S3] [S1]
Broader peptide reviews place peptide actions within signaling networks such as PI3K/Akt, mTOR, MAPK, TGF‑β, and AMPK that are relevant to tissue regeneration and metabolic regulation, but direct mechanistic clinical data for tesamorelin beyond GH/IGF‑1 axis engagement are not detailed in the reviewed excerpts. [S1] [S4]
Reported study designs and protocol examples
Randomized, double‑blind clinical trial data have been reported among people with HIV and metabolic dysfunction‑associated steatotic liver disease comparing tesamorelin 2 mg once daily with placebo over a 12‑month treatment period, with imaging outcomes including visceral fat cross‑sectional area (MRI), hepatic fat fraction (proton MR spectroscopy), and trunk‑to‑appendicular fat ratio (DXA). [S5]
Regulatory summaries and historic reports note that tesamorelin underwent trials leading to regulatory approval for reduction of excess abdominal fat in HIV‑infected patients with lipodystrophy (approval documented in 2010), but full phase‑III protocol details are not provided in the reviewed excerpt. [S3] [S5]
Protocol table from cited sources
The following table summarizes protocol details reported in cited studies. These details are provided as literature context only and are not recommendations or instructions.
| Source | Study Type | Model / Subject | Amount Reported | Route Reported | Frequency | Duration | Notes |
|---|---|---|---|---|---|---|---|
| [S5] | Randomized Controlled Trial | People with HIV and metabolic dysfunction‑associated steatotic liver disease (subset on INSTI‑based regimens) | 2 mg | not reported in the reviewed source | once daily | 12 months | Outcomes included visceral fat cross‑sectional area (MRI), hepatic fat fraction (proton MRS), and trunk‑to‑appendicular fat ratio (DXA); tesamorelin produced significant declines in these measures compared with placebo and had similar adverse event frequency, including hyperglycemia, between groups. |
| [S3] | Regulatory approval / clinical trial summary (news) | HIV‑infected patients with lipodystrophy | not reported in the reviewed source | not reported in the reviewed source | not reported in the reviewed source | not reported in the reviewed source | Tesamorelin (Egrifta) was approved in 2010 for reduction of excess abdominal fat in HIV‑infected patients with lipodystrophy; specific phase III protocol parameters are not detailed in the reviewed excerpt. |
Limitations and research gaps
- Most controlled clinical trial evidence for tesamorelin in the reviewed records is specific to people with HIV and abdominal fat accumulation; clinical evidence outside this indication (for example, orthopaedics or sports medicine) is limited or absent in the reviewed sources.
- Mechanistic descriptions in reviews link tesamorelin to GH/IGF‑1 signaling and broader regenerative pathways, but direct clinical mechanistic data beyond effects on body composition are not provided in the reviewed excerpts.
- Safety and efficacy data for non‑HIV indications are sparse in the reviewed literature, and reviews highlight the need for more rigorous human trials before broader clinical adoption.
Documentation checklist
- Confirm population studied (e.g., people with HIV) before extrapolating results to other groups.
- Verify reported endpoints and imaging modalities (MRI, proton MRS, DXA) when interpreting outcomes.
- Check whether route of administration and other protocol details are specified in the primary source before use in protocol planning (route not always reported in reviewed excerpts).
- Prioritize peer‑reviewed randomized controlled trial data over review‑level mechanistic hypotheses for clinical decision context.
Related research supplies
- Cold‑chain storage logs and temperature monitoring documentation
- Laboratory sample labeling supplies and tracking sheets
- Inventory tracking templates for controlled study products
- Surface and equipment compatible disinfectant product documentation
Research organization supplies: Common tools used for research documentation workflows may include lab notebooks, label makers, sample storage boxes, inventory stickers, and temperature log sheets.
Paid-link disclosure: Peptide Bio Index may earn a commission from qualifying purchases. As an Amazon Associate I earn from qualifying purchases.
Case with accessory space
Qunclay 14-Slot Vial Travel Case
A 14-slot case with additional compartments that can support organized research-supply storage. Use only for compatible materials and documented workflows.
Bulk technical cleaning
MG Chemicals 99.9% IPA Wipes
A bulk box of presaturated IPA wipes for compatible technical-cleaning tasks. Confirm material compatibility and ventilation requirements.
Label-printer refill
Phomemo M110 White Replacement Labels
White 1.57 × 0.78 inch replacement labels for compatible Phomemo printers. Confirm printer and label-size compatibility before ordering.
Product listings, specifications, and availability can change. Review the current Amazon listing and manufacturer instructions before ordering. These links are for research organization and compatible surface/equipment-cleaning workflows, not personal-use guidance.
Research Supply Note: For research-use-only sourcing, review current SourcePoint Research inventory and batch documentation at SourcePointResearch.com. Peptide Bio Index is affiliated with SourcePoint Research.
Sources and references
- [S1] Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews. 2026. PMID: 41490200. DOI: 10.5435/JAAOSGlobal-D-25-00236
- [S2] Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.. The American journal of sports medicine. 2026. PMID: 41476424. DOI: 10.1177/03635465251357593
- [S3] Grunfeld C, Dritselis A, Kirkpatrick P. Tesamorelin.. Nature reviews. Drug discovery. 2011. PMID: 21283099. DOI: 10.1038/nrd3362
- [S4] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.. Sports medicine (Auckland, N.Z.). 2026. PMID: 41966639. DOI: 10.1007/s40279-026-02437-0
- [S5] Russo SC, Ockene MW, Arpante AK, Johnson JE, Lee H, Toribio M. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.. AIDS (London, England). 2024. PMID: 38905488. DOI: 10.1097/QAD.0000000000003965
- [S6] O'Neal R. Tesamorelin update.. BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation. 2010. PMID: 21591600
Peptide Bio Index is affiliated with SourcePoint Research. Articles may link to SourcePointResearch.com and third-party affiliate products. As an Amazon Associate, Peptide Bio Index earns from qualifying purchases. Content is educational and research-literature focused only and is not medical advice, dosing guidance, or a personal-use recommendation.